Kazia Therapeutics Ltd KZIA:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:41 PM EST
11.30quote price arrow down-0.17 (-1.48%)
Volume
13,181
Close
11.47quote price arrow up+0.62 (+5.71%)
Volume
237,117
52 week range
2.47 - 15.85

...

Loading . . .

KEY STATS

  • Open11.33
  • Day High12.49
  • Day Low11.19
  • Prev Close10.85
  • 52 Week High15.85
  • 52 Week High Date11/18/20
  • 52 Week Low2.47
  • 52 Week Low Date04/03/20
  • Market Cap144.75M
  • Shares Out12.62M
  • 10 Day Average Volume0.29M
  • Dividend-
  • Dividend Yield-
  • Beta2.81
  • 1 Year % Change177.01

RATIOS/PROFITABILITY

  • EPS (TTM)-1.08
  • P/E (TTM)-10.58
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-8.737M
  • ROE (MRQ)-88.05%
  • Revenue (MRQ)50,000.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-18,918.77%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Kazia Therapeutics Ltd News

There is no recent news for this security.

Latest KZIA News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507)...
Iain Ross
Non-Executive Chairman
James Garner
Chief Executive Officer
Address
L 5 20 George St, Hornsby
Sydney, NSW
2077
Australia